Yahoo Web Search

Search results

1. • 

     TIME100 Health: Thomas Powles

     Time via AOL· 6 days ago

     Thomas Powles Credit - Courtesy Powles Bladder cancer is what Dr. Thomas Powles, a urologist at Queen Mary University of London, calls a “Cinderella <...

2. • TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...

     The Longview News-Journal· 5 days ago

     "The high complete response rate and durability of these responses observed in patients treated with TAR-200 underscores the potential of this treatment approach for patients ...

3. • 

     Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?

     Investor's Business Daily· 5 hours ago

     Meanwhile, Moderna is expanding its efforts in cancer treatment. The company is partnered with Merck...

4. • 

     Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data

     Benzinga· 2 days ago

     On Sunday, Johnson & Johnson JNJ ) released updated results from an open-label, multicenter,...

5. • TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...

     Quad-City Times· 5 days ago

     "The high complete response rate and durability of these responses observed in patients treated with TAR-200 underscores the potential of this treatment approach for patients ...

6. • 

     How mRNA vaccines could be personalized cancer cures

     Axios· 1 day ago

     Why it matters: This personalized approach could make conditions like melanoma and bladder, kidney, pancreatic and breast cancers treatable, and even...

7. • 

     New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy

     Verywell Health via Yahoo News· 6 days ago

     His recent Phase 1 trial showed the combination of two drugs showed high efficacy and was reasonably...

8. • 

     TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...

     The Journal Times· 5 days ago

     "The high complete response rate and durability of these responses observed in patients treated with...

9. • TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk...

     St. Louis Post-Dispatch· 5 days ago

     Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive ...

10. • Strengthening CAR-T Therapy to Work Against Solid Tumors

      WKRN Nashville· 3 hours ago

      The promising findings, reported today in Science Advances, involve CAR-T cell therapy, which supercharges the immune system to identify and attack cancer cells. "CAR-T cell ...